BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
May 15, 2025 • 7min
ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year
ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through over time. Plus, updates on programs for cholestatic diseases, Rhett Syndrome, and MASH.
May 14, 2025 • 10min
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A first program recently had its IND cleared.
May 14, 2025 • 9min
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies
CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered circular RNA in humans over a decade ago. They discuss potential use cases, including using it for in-vivo CAR-T, something that has been talked about a lot at this year's conference.
May 13, 2025 • 13min
Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans
He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and gene therapies progresses.
May 13, 2025 • 17min
Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized
Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized.
May 12, 2025 • 20min
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.
May 9, 2025 • 19min
Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera
He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on the value of being local for uncovering opportunities, and the state of the capital markets.
May 9, 2025 • 13min
With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers
CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews catalysts to watch for over the year ahead.
May 9, 2025 • 7min
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.
May 9, 2025 • 10min
Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform
CEO Alan Rigby talks about the work Epitopia does finding "Crypotgen" antigens for its own off-the-shelf cancer vaccines, and discusses what was appealing to Merck about the partnership.
